Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Vertex Pharmaceuticals
Vertex Pharmaceuticals
Vertex Leans into Gene Editing Space with Extended Arbor Pact
BioSpace
Thu, 01/12/23 - 10:41 am
Vertex Pharmaceuticals
Arbor Biotechnologies
gene editing
Fresh from Vertex payday, Entrada's DMD plans are derailed by FDA hold
Fierce Biotech
Tue, 12/20/22 - 10:42 am
Entrada Therapeutics
Vertex Pharmaceuticals
FDA
clinical trials
Duchenne Muscular Dystrophy
myotonic muscular dystrophy
ENTR-601-44
Vertex pays Entrada $224M for preclinical rare disease drug, opening new front in assault on dystrophy
Fierce Biotech
Thu, 12/8/22 - 10:35 am
Vertex Pharmaceuticals
Entrada Therapeutics
ENTR-701
myotonic muscular dystrophy
ASH preview – waiting for Editas
EP Vantage
Wed, 11/9/22 - 10:40 am
ASH 2022
sickle cell disease
Bluebird Bio
Sangamo BioSciences
Novartis
Editas Medicine
gene therapy
Vertex Pharmaceuticals
Sanofi
A Glimmer of Hope in the Quest for a Nonaddictive Painkiller
Bloomberg
Thu, 11/3/22 - 11:08 am
Vertex Pharmaceuticals
VX-548
non-opioid pain treatments
Vertex Shrugs Off Recent Malaise With A Third-Quarter Beat-And-Raise
Investors Business Daily
Sun, 10/30/22 - 04:11 pm
Vertex Pharmaceuticals
earnings
Few safe havens surface in another down quarter for biopharma
EP Vantage
Fri, 10/14/22 - 10:03 am
biopharma stocks
COVID-19
Eli Lilly
Bristol Myers Squibb
Merck
Daiichi Sankyo
Vertex Pharmaceuticals
Takeda
Neurocrine
Sarepta Therapeutics
Orion
Pfizer
GSK
Roche
Moderna Therapeutics
BeiGene
BioNTech
Novavax
CureVac
Vertex, after setbacks, moves forward with second-generation rare disease drug
BioPharma Dive
Tue, 10/11/22 - 04:07 pm
Vertex Pharmaceuticals
alpha 1-antitrypsin deficiency
clinical trials
Why Vertex Pharmaceuticals' Shares Rose 2.8% in September
Motley Fool
Wed, 10/5/22 - 10:33 am
Vertex Pharmaceuticals
Trikafta
R&D
cystic fibrosis
Vertex given green light to seek US approval of CRISPR-based therapy
BioPharma Dive
Wed, 09/28/22 - 12:01 am
Vertex Pharmaceuticals
CRISPR
CRISPR Therapeutics
FDA
exa-cel
beta thalassemia
sickle cell disease
Drug makers leave the pain behind
EP Vantage
Fri, 08/26/22 - 10:26 am
painkillers
Acadia
Eli Lilly
Ampio Pharmaceuticals
Aptinyx
Eliem Therapeutics
Vertanical
Teva Pharamceutical
Regeneron
Vivozon
Vertex Pharmaceuticals
Biogen
Where Will Vertex Pharmaceuticals Be in 1 Year?
Motley Fool
Tue, 08/23/22 - 10:38 am
Vertex Pharmaceuticals
cystic fibrosis
kidney disease
Vertex Advances VX-548 in Acute and Neuropathic Pain
Yahoo/Businesswire
Fri, 07/22/22 - 10:09 am
Vertex Pharmaceuticals
acute pain
neuropathic pain
FDA
VS-548
clinical trials
Few biopharma risers stand out at the half year
EP Vantage
Wed, 07/13/22 - 10:06 am
Lantheus Medical
Vertex Pharmaceuticals
Jazz Pharmaceuticals
COVID-19
Vertex Pharma (VRTX) to Acquire ViaCyte for $320 Million
Street Insider
Mon, 07/11/22 - 10:42 am
Vertex Pharmaceuticals
M&A
ViaCyte
type 1 diabetes
stem cells
Vertex, continuing its rebound, cleared to resume testing of diabetes cell therapy
BioPharma Dive
Wed, 07/6/22 - 10:33 am
Vertex Pharmaceuticals
type 1 diabetes
cell therapy
FDA
Aiming to be biggest biotech in Boston, Vertex plots 500-person cell, gene therapy R&D center
Fierce Biotech
Tue, 05/17/22 - 10:54 am
Vertex Pharmaceuticals
Boston
cell therapy
gene therapy
How Bad Is This News for Vertex Pharmaceuticals?
Motley Fool
Wed, 05/4/22 - 10:28 am
Vertex Pharmaceuticals
VX-880
type 1 diabetes
FDA
Vertex Falls After FDA Halts Diabetes Study in Surprise Move
Yahoo/Bloomberg
Mon, 05/2/22 - 11:01 am
Vertex Pharmaceuticals
FDA
type 1 diabetes
clinical trials
VX-880
5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates
Yahoo/Zacks.com
Fri, 04/29/22 - 10:17 am
COVID-19
earnings
Novo Nordisk
Biogen
Regeneron
Moderna Therapeutics
Vertex Pharmaceuticals
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »